Clinical trials: Systemic Lupus
Systemic Lupus Erythematosus
Clonal Hematopoiesis of Indeterminate Potential and Accelerated Atherosclerosis in Systemic Lupus Erythematosus
Accelerated atherosclerosis in patients with systemic lupus erythematosus (SLE) is not fully explained by Framingham risk factors.
- Trial name
- HEMATOPLUS (NCT05146414)
- Where
- France
- Volunteers
- 500 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Systemic Lupus Erythematosus, Immunoglobulin A Nephropathy
The Genital Tract Microflora in Women With Systemic Lupus Erythematosus (SLE) and Immunoglobulin A (IgA) Nephropathy.
The study hypothesis: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a broad spectrum of clinical manifestations. Its mechanisms are not well understood.
- Trial name
- NCT05132621
- Testing
- Smear
- Where
- Poland
- Volunteers
- 150 people
- Sponsor
- Medical University of Warsaw
Lupus Erythematosus, Systemic
BI 705564 in Patients With Systemic Lupus Erythematosus (SLE)
The main objective of this study is to assess the safety, tolerability and pharmacokinetics of orally administered BI 705564 in patients with systemic lupus erythematosus
- Trial name
- NCT03771885
- Testing
- BI 705564
- Sponsor
- Boehringer Ingelheim
Systemic Lupus Erythematosus, Muscle Pain
Laser Therapy for Patients With Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is a chronic, autoimmune disease that has detrimental effects on connective tissue and other organs.
- Conditions
- Systemic Lupus Erythematosus, Muscle Pain, Chewing Function
- Trial name
- NCT04453215
- Testing
- GaAlAs semiconductor diode laser device
- Where
- Turkey (Türkiye)
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- Dr. Merve Benli
Systemic Lupus Erythematosus
Evaluation of Slit2 in Systemic Lupus Erythematosus and Systemic Sclerosis Patients
1.Assessment of slit2 level in SLE patients and its correlation with disease activity. 2-Assessment of slit2 level in SSC patients and its correlation with disease activity
- Trial name
- NCT05105217
- Testing
- Slit2 biomarker
- Volunteers
- 85 people
- Sponsor
- Assiut University
Autoimmune Hemolytic Anemia, Systemic Lupus Erythematosus
Reappraisal of the Therapies of Refractory Autoimmune Hemolytic Anemia in Systemic Lupus Erythematosus
There is a deficiency in guidelines about the treatment of autoimmune hemolytic anemia in systemic lupus erythematosus (SLE), especially in refractory cases.
- Trial name
- NCT05057481
- Testing
- Mycophenolate Mofetil 500mg, Rituximab
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Assiut University
Systemic Lupus Erythematosus
Exercise and Nutrition Recommendations for Patients Using Glucocorticoids (ENRG)
This parallel-group randomized, controlled, clinical trial aims to investigate the influence of a 6-month home-based, remotely-monitored, exercise training intervention on musculoskeletal health in patients with Systemic Lupus…
- Trial name
- NCT05090189
- Testing
- Exercise Training
- Where
- Brazil
- Volunteers
- 50 people
- Sponsor
- Bruno Gualano
Systemic Lupus Erythematosus
A Study Evaluating the Effects of GLPG3970 Given as Oral Treatment for 12 Weeks in Adults With Systemic Lupus Erythematosus
This is a first exploration of GLPG3970 in subjects with active systemic lupus erythematosus (SLE) to evaluate the effect on disease biomarkers and to determine its pharmacokinetics (PK) profile, safety and tolerability, and…
- Trial name
- TAPINOMA (NCT04700267)
- Testing
- GLPG3970 film-coated tablet
- Where
- 14 sites in Bulgaria, Moldova and 3 more
- Volunteers
- 11 people
- Sponsor
- Lakefront Biotherapeutics NV
Systemic Lupus Erythematosus (SLE)
Omega-3 Replacement With Krill Oil in Disease Management of SLE
A randomized, double-blind controlled, multicenter study in SLE patients given AKBM-3031or placebo for 24 weeks (randomized period) and followed by an open label extension (OLE) treatment with AKBM-3031 for the next 24 weeks.
- Trial name
- ORKIDS (NCT03626311)
- Testing
- AKBM-3031
- Where
- 19 sites in United States, Canada
- Volunteers
- 76 people
- Sponsor
- Aker BioMarine Human Ingredients AS
Systemic Lupus Erythematosus, Periodontitis
Treatment of Periodontal Disease in Systemic Lupus Erythematosus
The primary objective of this study is to: Part 1 - Baseline Comparisons The primary objective of Part 1 is to: Investigate the association between SLE and a measures of vascular health (brachial artery flow-mediated dilatyation)…
- Trial name
- NCT04046172
- Testing
- supra/sub gingival root surface debridement, supra-gingival scaling and polishing
- Where
- United Kingdom
- Volunteers
- 200 people
- Sponsor
- University College, London
Systemic Lupus Erythematosus Nephritis
Anti-ficolin-3 Antibodies in Lupus Nephritis
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by the production of multiple autoantibodies and accumulation of immune complexes resulting in systemic inflammatory response and tissue damage.
- Trial name
- IgFicoLupus (NCT03842787)
- Testing
- Biological analysis
- Where
- France
- Volunteers
- 4 people
- Sponsor
- University Hospital, Grenoble
Systemic Lupus Erythematosus
Multicomponent Strategy to Implement a Clinical Practice Guideline and Improve Health Outcomes in People With SLE
Principal objective: To produce scientific knowledge on the effectiveness and cost-effectiveness of a multicomponent intervention for knowledge transfer and implementing a Clinical Practice Guideline (CPG) for Systemic Lupus…
- Trial name
- NCT03537638
- Testing
- Multicomponent intervention
- Where
- Spain
- Volunteers
- 237 people
- Sponsor
- Servicio Canario de Salud
Rheumatoid Arthritis, Lupus Erythematosus, Systemic
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
Fatigue is common and disabling for most patients with inflammatory rheumatic disease. Therapies designed to improve physical activity and 'talking' treatments, which positively help patients change the way they think and behave…
- Conditions
- Rheumatoid Arthritis, Lupus Erythematosus, Systemic, Axial Spondyloarthritis, Psoriatic Arthritis
- Trial name
- LIFT (NCT03248518)
- Testing
- Usual Care, Cognitive behavioural approach, Personalised Exercise Programme
- Where
- 6 sites in United Kingdom
- Volunteers
- 368 people
- Sponsor
- University of Aberdeen
Systemic Lupus Erythematosus
IL17 in Systemic Lupus Erythematosus Patients: Association With Disease Activity and Organ Damage
Many laboratory markers can be measured for assessment of Lupus activity as aberrant manufacturing and imbalance of the cytokines of T-helper cell which already have been implicated within autoimmunity pathogenesis as IL-18 and…
- Trial name
- NCT05045417
- Testing
- Serum level of IL-17
- Where
- Egypt
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Sohag University
Systemic Lupus Erythematosus
Role of PPAR-y Agonists in Immunomodulation and Vascular Prevention in SLE (PPAR-SLE)
Background: Lupus causes a person s immune system to attack the body. It can cause blood vessel problems, heart attack, or stroke. Researchers want to see if the drug pioglitazone may help.
- Trial name
- NCT02338999
- Testing
- PET/CT, Pioglitazone
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Interstitial Lung Disease, Systemic Autoimmune Disease
ILD-SARDs Registry and Biorepository
A complex interaction between demographic, environmental and genetic mechanisms impact the onset, severity and outcome of ILD-SARDs through dysregulation of the immune system and lung pro-biotic pathways.
- Conditions
- Interstitial Lung Disease, Systemic Autoimmune Disease, Rheumatic Diseases, Rheumatic Arthritis
- Trial name
- ILD-SARDs (NCT05007340)
- Testing
- Blood draws, Other biological samples to biobank (skin, lung and muscle biopsies; bronchoalveolar lavage (BAL fluid), Clinical data collection
- Where
- Canada
- Volunteers
- 252 people, healthy volunteers welcome
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Systemic Lupus Erythematosus
Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE)
The purpose of this study is to evaluate the efficacy, safety, and tolerability of belimumab in adult patients of black race with systemic lupus erythematosus (SLE; lupus).
- Trial name
- EMBRACE (NCT01632241)
- Testing
- Belimumab 10 mg/kg plus standard therapy, Standard therapy
- Where
- 96 sites in United States, Brazil and 4 more
- Volunteers
- 503 people
- Sponsor
- Human Genome Sciences Inc., a GSK Company
Pulmonary Arterial Hypertension, Systemic Sclerosis
Volatile Organic Compounds (VOCs) as a Biomarker in Immune-mediated Pulmonary Arterial Hypertension (PAH)
Aim: to investigate the role of inflammation and auto-immunity in pulmonary arterial hypertension by using the profile of volatile organic compounds.
- Conditions
- Pulmonary Arterial Hypertension, Systemic Sclerosis, Systemic Lupus
- Trial name
- VOC-PAH (NCT03819777)
- Where
- Netherlands
- Volunteers
- 150 people
- Sponsor
- Maastricht University Medical Center
SLE (Systemic Lupus)
National Systemic Lupus Erythematosus Prospective Cohort, Saudi Arabia
SLE disease in Saudi Arabia is yet not well defined especially in a population with high consanguinity and high inbreeding coefficient . Up until now, there has been no prospective cohort study for SLE patients in Saudi Arabia.
- Trial name
- NCT04604990
- Where
- Saudi Arabia
- Volunteers
- 1,000 people
- Sponsor
- King Saud University
Systemic Lupus Erythematosus, Autoimmune Diseases
A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Systemic Lupus Erythematosus
A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Systemic Lupus Erythematosus
- Trial name
- NCT05030779
- Testing
- Assigned Interventions CD19/BCMA CAR T-cells
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Zhejiang University